HK1094769A1 - Pharmaceutical compositions based on idazoxan saltor one of its polymorphs - Google Patents

Pharmaceutical compositions based on idazoxan saltor one of its polymorphs

Info

Publication number
HK1094769A1
HK1094769A1 HK07100684A HK07100684A HK1094769A1 HK 1094769 A1 HK1094769 A1 HK 1094769A1 HK 07100684 A HK07100684 A HK 07100684A HK 07100684 A HK07100684 A HK 07100684A HK 1094769 A1 HK1094769 A1 HK 1094769A1
Authority
HK
Hong Kong
Prior art keywords
idazoxan
pharmaceutical composition
neuroleptic
exhibiting
tablet
Prior art date
Application number
HK07100684A
Other languages
English (en)
Inventor
Joel Bougaret
Jean-Louis Avan
Roland Segonds
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HK1094769A1 publication Critical patent/HK1094769A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK07100684A 2003-10-28 2007-01-19 Pharmaceutical compositions based on idazoxan saltor one of its polymorphs HK1094769A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312626A FR2861299B1 (fr) 2003-10-28 2003-10-28 Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
PCT/FR2004/002773 WO2005041956A1 (fr) 2003-10-28 2004-10-28 Compositions pharmaceutiques a base de sel d’idazoxan ou l’un de ses polymorphes

Publications (1)

Publication Number Publication Date
HK1094769A1 true HK1094769A1 (en) 2007-04-13

Family

ID=34400871

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100684A HK1094769A1 (en) 2003-10-28 2007-01-19 Pharmaceutical compositions based on idazoxan saltor one of its polymorphs

Country Status (19)

Country Link
US (2) US7338970B2 (zh)
EP (1) EP1682124B1 (zh)
JP (1) JP5160090B2 (zh)
CN (2) CN1870993B (zh)
AT (1) ATE381331T1 (zh)
AU (1) AU2004285316B2 (zh)
BR (1) BRPI0416006B1 (zh)
CA (1) CA2542752A1 (zh)
CY (1) CY1107304T1 (zh)
DE (1) DE602004010837T2 (zh)
DK (1) DK1682124T3 (zh)
ES (1) ES2297525T3 (zh)
FR (1) FR2861299B1 (zh)
HK (1) HK1094769A1 (zh)
HR (1) HRP20080108T3 (zh)
MX (1) MXPA06004717A (zh)
PL (1) PL1682124T3 (zh)
PT (1) PT1682124E (zh)
WO (1) WO2005041956A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476307B2 (en) * 2003-10-28 2013-07-02 Pierre Fabre Medicament Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2023159145A1 (en) * 2022-02-16 2023-08-24 Terran Biosciences, Inc. Deuterated idazoxan and methods of use thereof
CN117338772B (zh) * 2023-11-22 2024-04-09 徐州医科大学 一种药物组合物及其在制备用于预防和/或治疗重性抑郁障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH16249A (en) * 1980-02-04 1983-08-16 Reckitt & Colmann Prod Ltd Imidazoline derivatives,its pharmaceutical composition and method of use
US4541893A (en) * 1984-05-15 1985-09-17 Advanced Micro Devices, Inc. Process for fabricating pedestal interconnections between conductive layers in an integrated circuit
FR2698789B1 (fr) 1992-12-07 1995-03-03 Pf Medicament Utilisation de l'idazoxan et ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson et de son évolution.
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5574059A (en) * 1995-10-27 1996-11-12 Cornell Research Foundation, Inc. Treating disorders mediated by vascular smooth muscle cell proliferation
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
US6232215B1 (en) * 1996-09-18 2001-05-15 United Microelectronics Corp. Method for forming increased density for interconnection metallization
FR2774811B1 (fr) * 1998-02-10 2003-05-09 Sgs Thomson Microelectronics Procede de formation de lignes conductrices sur des circuits integres
FR2801786B1 (fr) * 1999-12-01 2002-03-01 Fabre Pierre Cosmetique Nouvelles compositions topiques a base d'idazoxan et de cafeine ou de ses derives solubles et leur utilisation comme amincissant et/ou dans le traitement de la cellulite

Also Published As

Publication number Publication date
EP1682124A1 (fr) 2006-07-26
CN1870993A (zh) 2006-11-29
US7338970B2 (en) 2008-03-04
WO2005041956A1 (fr) 2005-05-12
FR2861299A1 (fr) 2005-04-29
DE602004010837D1 (de) 2008-01-31
JP2007509911A (ja) 2007-04-19
US20080113022A1 (en) 2008-05-15
CN1870993B (zh) 2012-04-04
DE602004010837T2 (de) 2008-12-11
PT1682124E (pt) 2008-03-05
MXPA06004717A (es) 2006-07-05
AU2004285316B2 (en) 2010-08-19
FR2861299B1 (fr) 2006-01-27
ATE381331T1 (de) 2008-01-15
ES2297525T3 (es) 2008-05-01
BRPI0416006B1 (pt) 2019-02-05
CN102349873A (zh) 2012-02-15
CA2542752A1 (fr) 2005-05-12
DK1682124T3 (da) 2008-04-28
AU2004285316A1 (en) 2005-05-12
JP5160090B2 (ja) 2013-03-13
PL1682124T3 (pl) 2008-05-30
US8124640B2 (en) 2012-02-28
CN102349873B (zh) 2013-09-25
HRP20080108T3 (en) 2008-04-30
US20050090537A1 (en) 2005-04-28
CY1107304T1 (el) 2012-11-21
EP1682124B1 (fr) 2007-12-19
BRPI0416006A (pt) 2007-01-02

Similar Documents

Publication Publication Date Title
AU2015213778B2 (en) Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
Keck et al. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications
HRP20080108T3 (en) Pharmaceutical compositions based on idazoxan salt or one of its polymorphs
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
US20050233010A1 (en) Lithium combinations, and uses related thereto
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
CA2332408A1 (en) Combination therapy for treatment of bipolar disorders
JP6406713B2 (ja) 低用量薬剤によるうつ病および他の疾患の処置
JP2008534592A5 (zh)
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
MX2008012094A (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion.
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
CA2507002A1 (en) Solid drug for oral use
HRP20090569T1 (hr) Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
US20220096444A1 (en) Prophylactic or therapeutic agent for delirium
JP2007516193A5 (zh)
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
AU4062900A (en) Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
WO2003105902A1 (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
CA2521182A1 (en) Composition for improving cognition and memory
GEP20074225B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Müller-Spahn Current use of atypical antipsychotics
TW200513462A (en) Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191026